03:57 AM EDT, 10/11/2024 (MT Newswires) -- Burning Rock Biotech ( BNR ) and Dizal said Thursday that China's National Medical Products Administration has granted marketing approval for their jointly developed companion lung cancer diagnostic for the non-small cell lung cancer patients treatment sunvozertinib.

The approval of the companion diagnostic test is the result of the development of Burning Rock's LungCure diagnostic kit and Dizal's sunvozertinib.

The approval was based on the results of a study of sunvozertinib in platinum-based chemotherapy pretreated non-small cell lung cancer patients that met its primary endpoint in 61% of cases.

Price: 3.4500, Change: +0.17, Percent Change: +5.02